Brief: Barinthus Bio Announces Strategic Focus In Immunology And Inflammation, Provides A Financial Update

Barinthus Biotherapeutics

10/01/2025 13:23

Jan 10 (Reuters) - Barinthus Biotherapeutics PLC
 2ABy.F :
    * BARINTHUS BIO ANNOUNCES STRATEGIC FOCUS IN IMMUNOLOGY AND
INFLAMMATION (I&I) AND PROVIDES A FINANCIAL UPDATE
    * BARINTHUS BIOTHERAPEUTICS PLC: PRIORITIZING VTP-1000
DEVELOPMENT
IN CELIAC DISEASE, PHASE 1 DATA EXPECTED IN MID-2025
    * BARINTHUS BIOTHERAPEUTICS PLC: POSTPONING FURTHER CLINICAL
DEVELOPMENT OF VTP-300 IN CHRONIC HEPATITIS B (CHB) UNTIL A
PARTNER IS IDENTIFIED
    * BARINTHUS BIOTHERAPEUTICS PLC: EXTENDING CASH RUNWAY TO
START OF
2027 BY REDUCING COSTS
    * BARINTHUS BIOTHERAPEUTICS PLC: APPROXIMATE 65% REDUCTION
IN
WORKFORCE AND EXPECTED CLOSURE OF U.K. SITE
    * BARINTHUS BIOTHERAPEUTICS PLC: FUTURE OPERATIONS WILL BE
FOCUSED
AT U.S. SITE
    * BARINTHUS BIOTHERAPEUTICS PLC: AS PART OF RESTRUCTURING,
U.K COO
& CFO WILL LEAVE COMPANY

Source text:  urn:newsml:reuters.com:*:nGNX5pWmkl
Further company coverage:  2ABy.F 

 ((Reuters.Briefs@thomsonreuters.com;))